



Robert Greene Sterne  
Jorge A. Goldstein  
David K.S. Cormwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
John M. Covert  
Robert C. Millonig  
Donald J. Featherstone  
Timothy J. Shea, Jr  
Michael V. Messinger  
Judith U. Kim  
Patrick E. Garrett

Jeffrey T. Helvey  
Eldora L. Ellison  
Thomas C. Fiala  
Donald R. Banowitz  
Peter A. Jackman  
Jeffrey S. Weaver  
Brian J. Del Buono  
Mark Fox Evens  
Edward W. Yee  
Vincent L. Capuano  
Virgil Lee Beaston  
Theodore A. Wood  
Elizabeth J. Haanes  
Joseph S. Ostroff  
Daniel A. Klein  
Jason D. Eisenberg  
Michael D. Specht

Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis  
Ann E. Summerfield  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gabby L. Longworth  
Lori A. Gordon  
Laura A. Vogel  
Bryan S. Wade  
Bashir M.S. Ali  
Shannon A. Carroll  
Anbar F. Khal  
Michelle K. Holoubek  
Marsha A. Rose  
Young Tang

Christopher J. Walsh  
W. Blake Coblenz  
James J. Pohl\*  
John T. Haran  
Mark W. Rygiel  
Kevin W. McCabe  
Michael R. Malek\*  
Doyle A. Siever\*  
Ulrike Winkler\*


**Registered Patent Agents\***  
Karen R. Markowicz  
Matthew J. Dowd  
Katrina Yujian Pei Quach  
Bryan L. Skelton  
Robert A. Schwartzman  
Julie A. Heider  
Mita Mukherjee

Scott M. Woodhouse  
Peter A. Socarras  
Jeffrey K. Mills  
Danielle L. Letting  
Lori Brandes  
Steven C. Oppenheimer

**Of Counsel**  
Edward J. Kessler  
Kenneth C. Bass III  
Marvin C. Guthrie

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Practice Limited to  
Federal Agencies

December 13, 2006



Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**WRITER'S DIRECT NUMBER:**  
(202) 772-8822  
**INTERNET ADDRESS:**  
SCARROLL@SKGF.COM

**Art Unit 1646**  
**Via Hand Carry to Examiner Claire M. Kaufman**  
**Remsen Bldg., 4th Floor, East Corridor, Room 85**  
**400 Dulaney Street**

Re: U.S. Utility Patent Application  
Application No. 10/648,825; Filed: August 27, 2003  
For: **Death Domain Containing Receptor-5 Antibodies and Methods of Use**  
**(As Amended)**  
Inventors: Ni *et al.*  
Our Ref: 1488.131000C/EJH/SAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Credit Card Payment Form (PTO-2038) in the amount of \$180.00 to cover IDS fee;
2. Tenth Supplemental Information Disclosure Statement Filing under 37 C.F.R. §1.97(c);
3. Form PTO/SB/08A two (2) page listing cited documents AK2-AA5, and AL5-AN5;
4. Form PTO/SB/08B thirteen (13) pages listing cited documents AR35-AT71;
5. Copies of cited documents AL5-AN5, and AR35-AR71; and
6. A return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
December 13, 2006  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.  
Attorney for Applicants  
Registration No. 58,240

EJH/SAC/JMD/tts/rjv  
Enclosures

619146v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

On re application of:

Ni *et al.*

Appl. No.: 10/648,825

Filed: August 27, 2003

For: **Death Domain Containing  
Receptor-5 Antibodies and  
Methods of Use (As Amended)**

Confirmation No.: 3624

Art Unit: 1646

Examiner: Kaufman, Claire M.

Atty. Docket: 1488.131000C/EJH/SAC

**Tenth Supplemental Information Disclosure Statement  
Filing under 37 C.F.R. § 1.97(c).**

***Mail Stop Amendment***

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

12/14/2006 HMARZ11 00000026 10648825

01 FC:1006

100.00 0P

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Tenth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Ninth Information Disclosure Statement filed on November 4, 2005 in connection with the above-captioned application.

Copies of **AL5-AN5**, and **AR35** to **AR71** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent publications, documents **AK2** to **AA5** cited on the attached IDS Form PTO/SB/08A, are not submitted. In addition, a copy of documents **AS71** and **AT71** are not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or

portion of the application which caused it to be listed) is sua sponte waived where the cited pending application is stored in the USPTO's IFW system."

The Examiner's attention is directed to the following related U.S. Patent Applications:

U.S. Patent Application No. 10/979,831, inventors Ni *et al.*, filed November 3, 2004, published as US2005/0233958 A1, cited herein as **AF4**;

U.S. Provisional Patent Application No. 60/040,846, inventors Ni *et al.*, filed March 17, 1997, not published, cited herein at **AT65**;

U.S. Provisional Patent Application No. 60/054,021, inventors Ni *et al.*, filed July 29, 1997, not published, cited herein at **AS66**;

U.S. Provisional Patent Application No. 60/132,498, inventors Ni *et al.*, filed May 4, 1999, not published, cited herein at **AR67**;

U.S. Provisional Patent Application No. 60/133,238, inventors Ni *et al.*, filed May 7, 1999, not published, cited herein at **AS67**; and

U.S. Provisional Patent Application No. 60/148,939, inventors Ni *et al.*, filed August 13, 1999, not published, cited herein at **AT67**.

In addition, the Examiner's attention is directed to the following Interference Nos. 105,361; 105,240; 105,380 and 105,381 which are directed to related subject matter. For the convenience of the Examiner, Applicants have provided a copy of the motion lists filed by each party in Interference Nos. 105,361; 105,240; 105,380 and 105,381 cited

herein as documents **AR68-AT70**. Applicants have also cited patents, patent applications, and non-patent references listed in Applicants' Exhibit Lists for Interference Nos. 105,361; 105,240; 105,380 and 105,381 that have not already been made of record in the above-captioned application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an


action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.




Shannon A. Carroll, Ph.D.  
Attorney for Applicants  
Registration No. 58,240

Date:

December 13, 2006

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

618013v1



Equivalent of Form PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form PTO

# **TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

## **Complete if Known**

Application Number	10/648,825
Filing Date	August 27, 2003
First Named Inventor	Ni, Jian
Art Unit	1646
Examiner Name	KAUFMAN, Claire M.
Attorney Docket Number	1488.131000C/EJH/SAC

## **U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AK2	4,411,993	10/25/1983	Gillis	
	AA3	5,565,332	10/15/1996	Hoogenboom <i>et al.</i>	
	AB3	5,910,574	06/08/1999	Presta <i>et al.</i>	
	AC3	6,072,047	06/06/2000	Rauch <i>et al.</i>	
	AD3	6,252,050 B1	06/26/2001	Ashkenazi <i>et al.</i>	
	AE3	6,342,369 B1	01/29/2002	Ashkenazi	
	AF3	6,455,040 B1	09/24/2002	Wei <i>et al.</i>	
	AG3	6,569,642 B1	05/27/2003	Rauch <i>et al.</i>	
	AH3	6,635,743 B1	10/21/2003	Ebner <i>et al.</i>	
	AI3	6,642,358 B1	11/04/2003	Rauch <i>et al.</i>	
	AJ3	6,689,744 B2	02/10/2004	Gao <i>et al.</i>	
	AK3	2002/0004227 A1	01/10/2002	Ashkenazi <i>et al.</i>	
	AA4	2002/0150985 A1	10/17/2002	Adams <i>et al.</i>	
	AB4	2003/0004313 A1	01/02/2003	Ashkenazi	
	AC4	2003/0017161 A1	01/23/2003	Ashkenazi <i>et al.</i>	
	AD4	2003/0148455 A1	08/07/2003	Adams <i>et al.</i>	
	AE4	2004/0009552 A1	01/15/2004	Adams <i>et al.</i>	
	AF4	2005/0233958 A1	10/20/2005	Ni <i>et al.</i>	
	AG4	2005/0282230 A1	12/22/2005	Ashkenazi <i>et al.</i>	
	AH4	2006/0035334 A1	02/16/2006	Adams <i>et al.</i>	

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
	AL5	WO 89/05859 A1	06/29/1989	The Upjohn Company; Regents of the University of Toledo	
	AM5	WO 92/01810 A1	02/06/1992	Lerner <i>et al.</i>	
	AN5	WO 03/038043 A2	05/08/2003	UAB Research Foundation	

## **U.S. PATENT DOCUMENTS**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

## TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

***Complete if Known***

Application Number	10/648,825
Filing Date	August 27, 2003
First Named Inventor	NI, Jian
Art Unit	1646
Examiner Name	KAUFMAN, Claire M.
Attorney Docket Number	1488.131000C/EJH/SAC

Sheet	2	of	2
-------	---	----	---

[illegible]

## FOREIGN PATENT DOCUMENTS


[illegible]

617796v1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/648,825
		Filing Date	August 27, 2003
		First Named Inventor	Ni, Jian
		Art Unit	1646
		Examiner Name	KAUFMAN, Claire M.
Sheet	1	of	13
		Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AR35	Ahn, E.-Y., <i>et al.</i> , "Calmodulin Binding to the Fas Death Domain," <i>J. Biol. Chem.</i> 279:5661-5666, JBC Papers in Press (February 2004)	
	AS35	Alderson, M.R., <i>et al.</i> , "Regulation of apoptosis and T cell activation by Fas-specific mAb," <i>Int. Immunol.</i> 6:1799-1806, Oxford University Press (1994)	
	AT35	Altschul, S.F., <i>et al.</i> , "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> 215:403-410, Academic Press (1990)	
	AR36	Andrés, M., <i>et al.</i> , "Characterization of specific corticosterone binding sites in adrenal cortex plasma membrane and their localization by autoradiographic studies," <i>Cell. Mol. Life. Sci.</i> 53:673-680, Birkhauser Verlag (September 1997)	
	AS36	Armitage, R.J., <i>et al.</i> , "Molecular and biological characterization of a murine ligand for CD40," <i>Nature</i> 357:80-82, Nature Publishing Group (1992)	
	AT36	Ashkenazi, A., <i>et al.</i> , "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," <i>Proc. Natl. Acad. Sci. USA</i> 88:10535-10539, National Academy of Sciences (1991)	
	AR37	Bennett, B.D., <i>et al.</i> , "Cloning and Characterization of <i>HTK</i> , a Novel Transmembrane Tyrosine Kinase of the <i>EPH</i> Subfamily," <i>J. Biol. Chem.</i> 269:14211-14218, American Society for Biochemistry and Molecular Biology, Inc. (1994)	
	AS37	Bodmer, J.-L., <i>et al.</i> , "TRAIL receptor-2 signals apoptosis through FADD and caspase-8," <i>Nat. Cell. Biol.</i> 2:241-243, Macmillian Magazines Ltd. (April 2000)	
	AT37	Boldin, M.P., <i>et al.</i> , "Self-association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects," <i>J. Biol. Chem.</i> 270:387-391, American Society for Biochemistry and Molecular Biology, Inc. (1995)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	2	of	13	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>	
	AR38	Brutlag, D.L., <i>et al.</i> , "Improved sensitivity of biological sequence database searches," <i>Comput. Appl. Biosci.</i> 6:237-245, Oxford University Press (1990)		
	AS38	Carter, B.D. and Lewin, G.R., "Neurotrophins Live or Let Die: Does p75 <sup>NTR</sup> Decide?," <i>Neuron</i> 18:187-190, Cell Press (February 1997)		
	AT38	Casaccia-Bonnefil, P., <i>et al.</i> , "Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75, <i>Nature</i> 383:716-719, Nature Publishing Group (October 1996)		
	AR39	Cervantes-Acosta, G., <i>et al.</i> , "Human Jurkat lymphocytes clones differ in their capacity to support productive human immunodeficiency virus type 1 multiplication," <i>J. Virol. Methods.</i> 92:207-213, Elsevier/North-Holland Biomedical Press (April 2001)		
	AS39	Chuntharapai, A., <i>et al.</i> , "Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4," <i>J. Immunol.</i> 166:4891-4898, American Association of Immunologists (April 2001)		
	AT39	Cifone, M.G., <i>et al.</i> , "Apoptotic Signaling through CD95 (Fas/Apo-1) Activates an Acidic Sphingomyelinase," <i>J. Exp. Med.</i> 177:1547-1552, Rockefeller University Press (1993)		
	AR40	Clewley, J.P. and Arnold, C., "Megalign: The Multiple Alignment Module of LASERGENE," in <i>Methods in Molecular Biology, Vol. 70: Sequence Data Analysis Guidebook</i> , Swindell, S.R., eds., Humana Press Inc., Totowa, NJ, pp. 119-129 (April 1997)		
	AS40	Clodi, K., <i>et al.</i> , "Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells," <i>Br. J. Haematol.</i> 111:580-586, Blackwell Science Ltd. (November 2000)		
	AT40	Colucci, S., <i>et al.</i> , "T cells support osteoclastogenesis in an vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction," <i>Blood</i> 104:3722-3730, The American Society of Hematology (December 2004)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	3	of	13	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>	
	AR41	Cordero, O.J., <i>et al.</i> , "Cell surface human $\alpha$ -L-fucosidase," <i>Eur. J. Biochem.</i> 268:3321-3331, Blackwell Science Ltd. (June 2001)		
	AS41	Cramer, S.D., <i>et al.</i> , "A Mouse Growth Hormone-binding Protein RIA: Concentrations in Maternal Serum during Pregnancy," <i>Endocrinology</i> 130:1074-1076, Endocrine Society (1992)		
	AT41	Devereux, J., <i>et al.</i> , "A comprehensive set of sequence analysis programs for the VAX," <i>Nucleic Acids Res.</i> 12:387-395, IRL Press Ltd. (1984)		
	AR42	Drosopoulos, K.G., <i>et al.</i> , "Transformation by Oncogenic RAS Sensitizes Human Colon Cells to TRAIL-induced Apoptosis by Up-regulating Death Receptor 4 and Death Receptor 5 through a MEK-dependent Pathway," <i>J. Biol. Chem.</i> 280:22856-22867, JBC Papers in Press (June 2005)		
	AS42	Emery, J.G., <i>et al.</i> , "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL," <i>J. Biol. Chem.</i> 273:14363-14367, American Society for Biochemistry and Molecular Biology, Inc. (June 1998)		
	AT42	Engelmann, H., <i>et al.</i> , "Antibodies to a Soluble Form of a Tumor Necrosis Factor (TNF) Receptor Have TNF-like Activity," <i>J. Biol. Chem.</i> 265:14497-14504, American Society for Biochemistry and Molecular Biology, Inc. (1990)		
	AR43	Espevik, T., <i>et al.</i> , "Characterization of Binding and Biological Effects of Monoclonal Antibodies Against a Human Tumor Necrosis Factor Receptor," <i>J. Exp. Med.</i> 171:415-426, Rockefeller University Press (1990)		
	AS43	Fadeel, B., <i>et al.</i> , "Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects <i>in vitro</i> ," <i>Int. Immunol.</i> 9:201-209, Oxford University Press (February 1997)		
	AT43	Feinstein, E., <i>et al.</i> , "The death domain: a module shared by proteins with diverse cellular functions," <i>Trends Biochem. Sci.</i> 20:342-344, Elsevier Trends Journals (1995)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	4	of	13	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T <sup>2</sup>
	AR44	Feldmann, M., <i>et al.</i> , "TNF $\alpha$ as a Therapeutic Target in Rheumatoid Arthritis," <i>Circ. Shock</i> 43:179-184, Wiley-Liss, Inc. (1994)		
	AS44	Fiumara, P., <i>et al.</i> , "Functional expression of receptor activator of nuclear factor $\kappa$ B in Hodgkin disease cell lines," <i>Blood</i> 98:2784-2790, The American Society of Hematology (November 2001)		
	AT44	Frade, J.M., <i>et al.</i> , "Induction of cell death by endogenous nerve growth factor through its p75 receptor, <i>Nature</i> 383:166-168, Macmillan Magazines Ltd. (September 1996)		
	AR45	Georgakis, G.V., <i>et al.</i> , "Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death," <i>Br. J. Haematol.</i> 130:501-510, Blackwell Publishing Ltd. (August 2005)		
	AS45	Griffith, T.S., <i>et al.</i> , "Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies," <i>J. Immunol.</i> 162:2597-2605, American Association of Immunologists (March 1999)		
	AT45	Guo, F., <i>et al.</i> , "Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells," <i>Cancer Res.</i> 64:2580-2589, American Association for Cancer Research (April 2004)		
	AR46	Herdegen, T., <i>et al.</i> , "Lasting N-Terminal Phosphorylation of c-Jun and Activation of c-Jun N-Terminal Kinases after Neuronal Injury," <i>J. Neurosci.</i> 18:5124-5135, Society for Neuroscience (July 1998)		
	AS46	Hiebert, S.W., <i>et al.</i> , "Cell Surface Expression and Orientation in Membranes of the 44-Amino-Acid SH Protein of Simian Virus 5," <i>J. Virol.</i> 62:2347-2357, American Society for Microbiology (1988)		
	AT46	Higgins, D.G. and Sharp, P.M., "CLUSTAL: a package for performing multiple sequence alignment on a microcomputer," <i>Gene.</i> 73:237-244, Elsevier Science Publishers B.V. (1988)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	5	of	13	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>	
	AR47	Hofmann, K. and Tschopp, J., "The death domain motif found in Fas (Apo-1) and TNF receptor is present in proteins involved in apoptosis and axonal guidance," <i>FEBS Lett.</i> 371:321-323, Elsevier Science B.V. (1995)		
	AS47	Huisman, C., <i>et al.</i> , "Paclitaxel Triggers Cell Death Primarily via Caspase-independent Routes in the Non-Small Cell Lung Cancer Cell Line NCI-H460," <i>Clin. Cancer Res.</i> 8:596-606, The Association (February 2002)		
	AT47	Ibrahim, S.M., <i>et al.</i> , "Pancreatic Adenocarcinoma Cell Lines Show Variable Susceptibility to TRAIL-Mediated Cell Death," <i>Pancreas</i> 23:72-79, Lippincott Williams & Wilkins (July 2001)		
	AR48	Ichikawa, K., <i>et al.</i> , "Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity," <i>Nat. Med.</i> 7:954-960, Nature Publishing Company (August 2001)		
	AS48	Itoh, N., <i>et al.</i> , "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> 66:233-243, Cell Press (1991)		
	AT48	Itoh, N. and Nagata, S., "A Novel Protein Domain Required for Apoptosis," <i>J. Biol. Chem.</i> 268:10932-10937, American Society for Biochemistry and Molecular Biology, Inc. (1993)		
	AR49	Kitson, J., <i>et al.</i> , "A death-domain-containing receptor that mediates apoptosis," <i>Nature</i> 384:372-375, Macmillan Magazines Ltd. (November 1996)		
	AS49	Köhler, G. and Milstein, C., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> 256:495-497, Nature Publishing Group (1975)		
	AT49	LeBlanc, H.N. and Ashkenazi, A., "Apo2L/TRAIL and its death and decoy receptors," <i>Cell Death Differ.</i> 10:66-75, Nature Publishing Group (July 2003)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to place (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	6	of	13	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>	
	AR50	Lum, J.J., <i>et al.</i> , "Induction of Cell Death in Human Immunodeficiency Virus-Infected Macrophages and Resting Memory CD4 T Cells by TRAIL/Apo2L," <i>J. Virol.</i> 75:11128-11136, American Society for Microbiology (November 2001)		
	AS50	Lum, J.J., <i>et al.</i> , "Acquired T-cell sensitivity to TRAIL mediated killing during HIV infection is regulated by CXCR4-gp120 interactions," <i>AIDS</i> 19:1125-1133, Lippincott Williams & Wilkins (July 2005)		
	AT50	Ma, Y., <i>et al.</i> , "Analysis of TRAIL receptor expression using anti-TRAIL death receptor-5 monoclonal antibodies," <i>Chin. Med. J.</i> 116:947-950, Chinese Medical Association (June 2003)		
	AR51	Maeda, T., <i>et al.</i> , "A Simple and Rapid Method for the Preparation of Plasma Membranes," <i>Biochim. Biophys. Acta.</i> 731:115-120, Elsevier Science Publishers B.V. (1983)		
	AS51	Maini, R.N., <i>et al.</i> , "Targeting TNF $\alpha$ for the therapy of rheumatoid arthritis," <i>Clin. Exp. Rheumatol.</i> 12/S11:S63-S66, Clinical And Experimental Rheumatology S.A.S. (1994)		
	AT51	Mapara, M.Y., <i>et al.</i> , "APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression," <i>Eur. J. Immunol.</i> 23:702-708, VCH Verlagsgesellschaft mbH (1993)		
	AR52	Marini, P., <i>et al.</i> , "Molecular requirements for the combined effects of TRAIL and ionising radiation," <i>Radiother. Oncol.</i> 68:189-198, Elsevier Ireland Ltd. (August 2003)		
	AS52	Mark, M.R., <i>et al.</i> , "rse, a Novel Receptor-type Tyrosine Kinase with Homology to Axl/Ufo, Is Expressed at High Levels in the Brain," <i>J. Biol. Chem.</i> 269:10720-10728, American Society for Biochemistry and Molecular biology, Inc. (1994)		
	AT52	Marsters, S.A., <i>et al.</i> , "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF- $\kappa$ B," <i>Curr. Biol.</i> 6:1669-1676, Current Biology Ltd. (December 1996)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	7	of	13	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T <sup>2</sup>
	AR53	Matsuda, T., <i>et al.</i> , "Resistance to Apo2 Ligand (Apo2L)/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Apoptosis and Constitutive Expression of Apo2L/TRAIL in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines," <i>J. Virol.</i> 79:1367-1378, American Society for Microbiology (February 2005)		
	AS53	Matysiak, M., <i>et al.</i> , "TRAIL induces death of human oligodendrocytes isolated from adult brain," <i>Brain</i> 125:2469-2480, Oxford University Press (November 2002)		
	AT53	Moldawer, L.L., "Interleukin-1, TNF $\alpha$ and Their Naturally Occurring Antagonists in Sepsis," <i>Blood Purif.</i> 11:128-133, S. Karger (1993)		
	AR54	Mori, E., <i>et al.</i> , "Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2," <i>Cell Death Diff.</i> 11:203-207, Nature Publishing Group (February 2004)		
	AS54	Mühlenbeck, F., <i>et al.</i> , "The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation," <i>J. Biol. Chem.</i> 275:32208-32213, American Society for Biochemistry and Molecular Biology, Inc. (October 2000)		
	AT54	Nagata, S. and Golstein, P., "The Fas Death Factor," <i>Science</i> 267:1449-1456, American Association for the Advancement of Science (1995)		
	AR55	Nakai, K. and Kanehisa, M., "A Knowledge Base for Predicting Protein Localization Sites in Eukaryotic Cells," <i>Genomics</i> 14:897-911, Harcourt Brace Jovanovich (1992)		
	AS55	O'Connell, J., <i>et al.</i> , "The Fas Counterattack: Fas-mediated T Cell Killing by Colon Cancer Cells Expressing Fas Ligand," <i>J. Exp. Med.</i> 184:1075-1082, Rockefeller University Press (September 1996)		
	AT55	Oehm, A., <i>et al.</i> , "Purification and Molecular Cloning of the APO-1 Cell Surface Antigen, a Member of the Tumor Necrosis Factor/Nerve Growth Factor Receptor Superfamily," <i>J. Biol. Chem.</i> 267:10709-10715, American Society for Biochemistry and Molecular Biology, Inc. (1992)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	8	of	13	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>	
	AR56	Ogasawara, J., <i>et al.</i> , "Lethal effect of the anti-Fas antibody in mice," <i>Nature</i> 364:806-809, Nature Publishing Group (1993)		
	AS56	O'Kennedy, R. and Roben, P., "Antibody engineering: an overview," in <i>Essays in Biochemistry, Volume 26</i> , Tipton, K.F., ed., Portland Press Ltd., London, U.K., pp. 59-75 (1991)		
	AT56	Parson, W., <i>et al.</i> , "Cancer cell line identification by short tandem repeat profiling: power and limitations," <i>FASEB J.</i> 19:434-436, Federation (January 2005)		
	AR57	Pawelec, G., <i>et al.</i> , "Constitutive interleukin 2 production by the JURKAT human leukemic T cell line," <i>Eur. J. Immunol.</i> 12:387-392, VCH Verlagsgesellschaft (1982)		
	AS57	Pukac, L., <i>et al.</i> , "HGS-ETRI, a fully human TRAIL-receptor I monoclonal antibody, induces cell death in multiple tumour types <i>in vitro</i> and <i>in vivo</i> ," <i>Br. J. Cancer</i> 92:1430-1441, Nature Publishing Group (April 2005)		
	AT57	Sheehan, K.C.F., <i>et al.</i> , "Monoclonal Antibodies specific for Murine p55 and p75 Tumor Necrosis Factor Receptors: Identification of a Novel In Vivo Role for p75," <i>J. Exp. Med.</i> 181:607-617, Rockefeller University Press (1995)		
	AR58	Simon, A.K., <i>et al.</i> , "Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: Sensitivity of human thymocytes," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 98:5158-5163, National Academy of Sciences (April 2001)		
	AS58	Söderström, T.S., <i>et al.</i> , "Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling in Activated T Cells Abrogates TRAIL-Induced Apoptosis Upstream of the Mitochondrial Amplification Loop and Caspase-8," <i>J. Immunol.</i> 169:2851-2860, American Association of Immunologists (September 2002)		
	AT58	Sprick, M.R., <i>et al.</i> , "FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2," <i>Immunity</i> 12:599-609, Cell Press (June 2000)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	9	of	13	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>	
	AR59	Srivastava, R.K., "TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer," <i>Neoplasia</i> 3:535-546, BC Decker (November – December 2001)		
	AS59	Suda, T., <i>et al.</i> , "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family," <i>Cell</i> 75:1169-1178, Cell Press (1993)		
	AT59	Tewari, M. and Dixit, V.M., "Recent advances in tumor necrosis factor and CD40 signaling," <i>Curr. Opin. Genet. Dev.</i> 6:39-44, Current Biology Ltd. (February 1996)		
	AR60	Trauth, B.C., <i>et al.</i> , "Monoclonal Antibody—Mediated Tumor Regression by Induction of Apoptosis," <i>Science</i> 245:301-305, American Association for the Advancement of Science (1989)		
	AS60	Trueba, M., <i>et al.</i> , "Specific Binding Sites for Corticosterone in Isolated Cells and Plasma Membrane from Rat Liver," <i>J. Membrane Biol.</i> 120:115-124, Springer-Verlag (1991)		
	AT60	Uckun, F.M., <i>et al.</i> , "Stimulation of Protein Tyrosine Phosphorylation, Phosphoinositide Turnover, and Multiple Previously Unidentified Serine/Threonine-specific Protein Kinases by the Pan-B-cell Receptor CD40/Bp50 at Discrete Development Stages of Human B-cell Ontogeny," <i>J. Biol. Chem.</i> 266:17478-17485, American Society for Biochemistry and Molecular Biology, Inc. (1991)		
	AR61	Ursini-Siegel, J., <i>et al.</i> , "TRAIL/Apo-2 Ligand Induces Primary Plasma Cell Apoptosis," <i>J. Immunol.</i> 169:5505-5513, American Association of Immunologists (November 2002)		
	AS61	Walczak, H., <i>et al.</i> , "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> 16:5386-5397, Oxford University Press (September 1997)		
	AT61	Ware, C.F., <i>et al.</i> , "Apoptosis Mediated by the TNF-Related Cytokine and Receptor Families," <i>J. Cell. Biochem.</i> 60:47-55, Wiley-Liss, Inc. (January 1996)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	10	of	13	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	AR62	Ware, C.F., <i>et al.</i> , "Tumor Necrosis Factor-Related Ligands and Receptors," in <i>The Cytokine Handbook</i> , 3 <sup>rd</sup> ed., Thomas, A.W., ed., Academic Press Limited, St. Louis, MO, pp.549-592 (July 1998)	
	AS62	Weller, M., <i>et al.</i> , "Fas/APO-1 GENE Transfer for Human Malignant Glioma," <i>Cancer Res.</i> 55:2936-2944, American Association for Cancer Research (1995)	
	AT62	Wen, J., <i>et al.</i> , "Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells," <i>Blood</i> 96:3900-3906, The American Society of Hematology (December 2000)	
	AR63	Wendling, U., <i>et al.</i> , "Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells," <i>Cell Death Diff.</i> 7:637-644, Nature Publishing Group (July 2000)	
	AS63	Wu, G.S., <i>et al.</i> , "KILLER/DR5 is DNA damage—inducible p53-regulated death receptor gene," <i>Nat. Genet.</i> 17:141-143, Nature Publishing Company (October 1997)	
	AT63	Yagita, H., <i>et al.</i> , "TRAIL and its receptors as targets for cancer therapy," <i>Cancer Sci.</i> 95:777-783, Blackwell Publishing (October 2004)	
	AR64	Yonehara, S., <i>et al.</i> , "A Cell-killing Monoclonal Antibody (ANTI-Fas) to a Cell Surface Antigen Co-downregulated with the Receptor of Tumor Necrosis Factor," <i>J. Exp. Med.</i> 169:1747-1756, Rockefeller University Press (1989)	
	AS64	Zhang, X.D., <i>et al.</i> , "Relation of TNF-related Apoptosis-inducing Ligand (TRAIL) Receptor and FLICE-inhibitory Protein Expression to TRAIL-induced Apoptosis of Melanoma," <i>Cancer Res.</i> 59:2747-2753, American Association for Cancer Research (June 1999)	
	AT64	NCBI Entrez, GenBank Report, Accession No. NP_002537 (February 2006)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	11	of	13	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AR65	Copy of U.S. Non-Provisional Application No. 08/857,216, inventors Ashkenazi, A.J., <i>et al.</i> , filed May 15, 1997 (NOT PUBLISHED)	
	AS65	Copy of U.S. Non-Provisional Application No. 09/020,746, inventors Ashkenazi, A.J., <i>et al.</i> , filed February 9, 1998 (NOT PUBLISHED)	
	AT65	Copy of U.S. Provisional Application No. 60/040,846, inventors Ni, J., <i>et al.</i> , filed March 17, 1997 (NOT PUBLISHED)	
	AR66	Copy of U.S. Provisional Application No. 60/046,615, inventor Ashkenazi, A.J., <i>et al.</i> , filed May 15, 1997 (NOT PUBLISHED)	
	AS66	Copy of U.S. Provisional Application No. 60/054,021, inventors Ni, J., <i>et al.</i> , filed July 29, 1997 (NOT PUBLISHED)	
	AT66	Copy of U.S. Provisional Application No. 60/072,481, inventors Chuntharapai, A., <i>et al.</i> , filed January 26, 1998 (NOT PUBLISHED)	
	AR67	Copy of U.S. Provisional Application No. 60/132,498, inventors Ni, J., <i>et al.</i> , filed May 4, 1999 (NOT PUBLISHED)	
	AS67	Copy of U.S. Provisional Application No. 60/133,238, inventors Ni, J., <i>et al.</i> , filed May 7, 1999 (NOT PUBLISHED)	
	AT67	Copy of U.S. Provisional Application No. 60/148,939, inventors Ni, J., <i>et al.</i> , filed August 13, 1999 (NOT PUBLISHED)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>TENTH SUPPLEMENTAL          INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	12	of	13	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AR68	Ni <i>et al.</i> , "Ni List of Intended Motions," October 20, 2005-Patent Interference No. 105,361	
	AS68	Ni <i>et al.</i> , "Ni Clarification of List of Intended Motions," October 21, 2005-Patent Interference No. 105,361	
	AT68	Ni <i>et al.</i> , "Ni List of Intended Motions," October 27, 2005-Patent Interference No. 105,240	
	AR69	Ni <i>et al.</i> , "Ni List of Intended Motions," November 17, 2005-Patent Interference No. 105,380	
	AS69	Ni <i>et al.</i> , "Ni List of Intended Motions," November 17, 2005-Patent Interference No. 105,381	
	AT69	Adams <i>et al.</i> , "Adams Motions List," October 20, 2005- Patent Interference No. 105,361	
	AR70	Rauch <i>et al.</i> , "Rauch List of Intended Substantive Motions," October 27, 2005-Patent Interference No. 105,240	
	AS70	Rauch <i>et al.</i> , "Rauch List of Intended Substantive Motions," November 23, 2005-Patent Interference No. 105,380	
	AT70	Rauch <i>et al.</i> , "Rauch List of Intended Substantive Motions," November 23, 2005-Patent Interference No. 105,381	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/648,825
				Filing Date	August 27, 2003
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	13	of	13	Attorney Docket Number	1488.131000C/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AR71	U.S. Provisional Application No. 60/074,119, inventor Ashkenazi, A.J., filed February 9, 1998 (NOT PUBLISHED)	
	AS71	U.S. Non-Provisional Application No. 11/455,062, inventor Ashkenazi, A.J., filed June 15, 2006 (NOT PUBLISHED)	
	AT71	U.S. Non-Provisional Application No. 11/483,978, inventors Adams, C., filed July 11, 2006 (NOT PUBLISHED)	

617346v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.